Captrust Financial Advisors Cassava Sciences Inc Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$17.22 - $38.47 $447 - $1,000	-26 Reduced 2.84%	891 $25,000
Q2 2022 Aug 16, 2022	BUY	$17.22 - $38.47 $688 - $1,538	40 Added 4.56%	917 $26,000
Q1 2022 May 16, 2022	BUY	$32.6 - $53.05 $23,700 - $38,567	727 Added 484.67%	877 $33,000
Q4 2021 Feb 14, 2022	BUY	$36.77 - $90.91 $367 - $909	10 Added 7.14%	150 $7,000
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $4,372 - $12,201	136 Added 3400.0%	140 $12,000
Q1 2021 May 17, 2021	BUY	$7.09 - $87.95 $28 - $351	4 New	4 $0

189

13.4M

2.96M

6.55M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $92.6M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.